ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor and Ureka

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today provided a progress update on activities around Covid-19.

On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new ‘Anti-Infective’ programs, one of which was in ‘Antivirals’. Investigation of the application of the Ureka peptide technologies within this Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies. Further exploratory work continues on this program.

As part of an overall evaluation of how we might apply our patented technologies to the fight against the Covid-19 epidemic, within our ‘Autoimmunity’ therapy  area, we have also been considering the unique way that Lupuzor™ interacts with the immune system and any potential application to Covid-19.

In this respect we note the results* of a recent study conducted at Emory University Atlanta GA,  suggesting that Covid-19 (SARS-COV-2) patients and systemic lupus erythematosus (SLE) patients experiencing flares might share similar inflammatory symptoms, underpinned by similar mechanisms (role of cytokines). Lupuzor™ is a modulator of the immune response and an anti-inflammatory agent, which has activity against SLE (lupus), an autoimmune disease, as well as against other inflammatory diseases. ImmuPharma, together with its US licencing partner, Avion Pharmaceuticals, will be progressing  Lupuzor™ into a new optimised international Phase III trial this year in lupus patients.

*“Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extraordinary B cell activation” -https://doi.org/10.1101/2020.04.29.20083717.

Given the findings of the Atlanta research group, we postulate that Lupuzor™ may help to reduce or perhaps prevent the occurrence of the cytokine storm seen in Covid-19 patients. Further exploratory work is ongoing to assess Lupuzor’s™ possible potential and clinical program in Covid-19 patients.

Commenting on the announcement, Dimitri Dimitriou, CEO and Dr Robert Zimmer, President & CSO of ImmuPharma said: “As the Covid-19 pandemic has unfolded, ImmuPharma has been evaluating how it can best contribute its expertise and resources to help in the global response. Using our longstanding knowledge of peptide based technology, provides us with a number of opportunities, to help bring together a therapy that could be effective against the inflammation that causes the serious complications of Covid-19. We look forward to providing further updates when appropriate”.   

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    ImmuPharma Major Opportunity Within Lupuzor Unlocked

    ImmuPharma (LON:IMM) announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals, a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas.

    Immupharma Plc

    ImmuPharma licenses lupus drug Lupuzor

    British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals. Avion and ImmuPharma will co-develop Lupuzor, including

    Immupharma Plc

    ImmuPharma Chairman explains why the Avion deal is so significant

    ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights of the deal, provides background on Avion,

    Immupharma Plc

    ImmuPharma to present at Biotech Showcase™ 2020

    ImmuPharma (LON:IMM), a specialist drug discovery and development company, has announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13-15 January 2020, at the Hilton, San Francisco Union Square. Dr

    Immupharma Plc

    Selena Gomez’s Lupus Flare Up at AMA’s

    Selena Gomez took to the American Music Awards (AMAs) stage for the first time in two years on Sunday night to perform two new tracks, ‘Lose You To Love Me’ and ‘Look At Her Now’. However, the

    Immupharma Plc

    Selena Gomez opens up on body-shaming comments

    Selena Gomez has admitted to struggling after being “attacked” for gaining weight following her lupus diagnosis. The chart-topping singer, 27, was diagnosed with lupus in 2015 and later underwent a kidney transplant due to complications from

    Immupharma Plc

    Lupus flare-ups could be linked to environmental factors

    Researchers have found that alteration in the environment and atomospheric factors could be associated with organ specific flare-ups of lupus among patients diagnosed with Systemic Lupus Erythematosus (SLE). The study results were presented at the 2019 ACR/ARP Annual Meeting.

    Immupharma Plc

    Lupus: the ‘invisible’ disease

    “Lupus mimics other diseases in your body and the community still doesn’t understand what it is,” says Daniella Djan who is living with the condition. Djan’s life changed irrevocably when she was 18-years-old and diagnosed with

    Immupharma Plc

    Managing Fatigue in Lupus

    Fatigue can be described as a feeling of weariness that is more extreme than simple tiredness. It often includes a lack of both physical and mental (or emotional) energy and motivation. The fatigue that many patients

    Immupharma Plc

    Look At Her Now: Selena Gomez

    Selena Gomez is back, and fans couldn’t be happier. It’s a triumphant return for Selena, who has suffered through health issues and break-ups over the past two years – but nothing can hold this girl down.

    Immupharma Plc

    Living with Lupus

    Another day, another torment. The same will follow the next day — the excruciating pain, inexplicable fatigue, and never-ending drowsiness. This is life with lupus, a rare, chronic autoimmune condition where the body’s immune system starts

    Immupharma Plc

    Lupus: 9 Early Signs that Mean You Have It

    Lupus is a serious disease which causes intense inflammation along with a variety of other symptoms. Each sufferer’s symptoms are quite different. Here, MusicSnake Magazine put together a list of 9 Early Signs that may mean you have lupus. Number One:

    Immupharma Plc

    Lupus and Celiac Disease: What Pharmacists Need to Know

    According to the Lupus Foundation of America, approximately 5 million people globally are affected by lupus and about 16,000 new cases are reported annually. Lupus occurs when the body’s immune system attacks the tissues and organs, which